January 11, 2024 09:45 AM EST
News Briefing

Der­ma­van­t's PhI­II eczema da­ta; Ox­ford's Ni­pah vac­cine; In­ven­ti­va's €25M life­line

Max Gelman

Senior Editor

Reynald Castañeda

Deputy Editor

Der­ma­vant re­port­ed new Phase III da­ta for its atopic der­mati­tis cream Vta­ma on Thurs­day morn­ing, say­ing more than 80% of par­tic­i­pants …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times